Positive Impact of a Pilot Pharmacist-Run Diabetes Pharmacotherapy Clinic in Solid Organ Transplant Recipients.
D. Newland, A. Edwards, R. Hall, P. Maxwell.
University Transplant Center, University Health System and The University of Texas Health Science Center at San Antonio, San Antonio, TX.
Meeting: 2016 American Transplant Congress
Abstract number: B233
Keywords: Kidney, Liver, Lung, Post-transplant diabetes
Session Information
Session Name: Poster Session B: Kidney: Cardiovascular and Metabolic
Session Type: Poster Session
Date: Sunday, June 12, 2016
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Halls C&D
Background: Post-transplant diabetes mellitus (PTDM) can lead to significant morbidity and cardiovascular death with a functioning graft. A paucity of literature exists regarding glycemic control in solid organ transplant (SOT) recipients, including pharmacist management of PTDM.
Objective: To assess the impact of pharmacist interventions on diabetes mellitus management in a pharmacist-run PTDM clinic.
Methods: A single-center, prospective, observational study was conducted of SOT recipients aged 18 years or older who were enrolled in a pilot pharmacist-managed PTDM pharmacotherapy clinic from 01/2015 – 06/2015. Primary outcome measures included changes in hemoglobin A1c (HbA1c) and average daily self-monitored blood glucose (SMBG) readings from enrollment to at least 3 months follow-up. Secondary outcome measures included changes in pre-meal, 2-hour post-dinner, and bedtime SMBG, as well as changes in lipids and body mass index. Other secondary outcomes included incidence of hypoglycemia, non-adherence, and diabetes-related inpatient hospitalizations prior to PTDM clinic enrollment and at time of clinic discharge.
Results: Twenty-four patients were included in the final analysis of this study. Improvements were realized in markers of glycemic control, including primary outcomes, fasting SMBG, and pre-lunch SMBG. Median HbA1c decreased significantly from 8.05 [IQR 6.33 – 11.75] % at baseline to 6.45 [IQR 6.05 – 7.3] % (p = 0.0010) at last follow-up encounter. Average daily SMBG decreased significantly from a median of 191 [IQR 138 – 232] mg/dL at baseline to 125 [IQR 111 – 167] mg/dL (p = 0.0023) at the final encounter. Median fasting and pre-lunch SMBG decreased significantly from 153 [IQR 117 – 208] mg/dL at baseline to 120 [IQR 102 – 134] mg/dL (p = 0.0064) and 212 [IQR 159 – 258] mg/dL to 122 [IQR 110 – 169] mg/dL (p = 0.0161), respectively. Changes from baseline in other SMBG values, lipid levels, and BMI were not statistically significant.
Conclusion: A pharmacist-managed post-transplant diabetes clinic can significantly impact glycemic control in SOT recipients.
CITATION INFORMATION: Newland D, Edwards A, Hall R, Maxwell P. Positive Impact of a Pilot Pharmacist-Run Diabetes Pharmacotherapy Clinic in Solid Organ Transplant Recipients. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:
Newland D, Edwards A, Hall R, Maxwell P. Positive Impact of a Pilot Pharmacist-Run Diabetes Pharmacotherapy Clinic in Solid Organ Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/positive-impact-of-a-pilot-pharmacist-run-diabetes-pharmacotherapy-clinic-in-solid-organ-transplant-recipients/. Accessed November 22, 2024.« Back to 2016 American Transplant Congress